Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.

ABSTRACT: Cognitive decline is a common feature of Parkinson's disease, and many of these cognitive deficits fail to respond to dopaminergic therapy. Therefore, targeting other neuromodulatory systems represents an important therapeutic strategy. Among these, the locus coeruleus-noradrenaline system has been extensively implicated in response inhibition deficits. Restoring noradrenaline levels using the noradrenergic reuptake inhibitor atomoxetine can improve response inhibition in some patients with Parkinson's disease, but there is considerable heterogeneity in treatment response. Accurately predicting the patients who would benefit from therapies targeting this neurotransmitter system remains a critical goal, in order to design the necessary clinical trials with stratified patient selection to es

SUBMITTER: O'Callaghan C 

PROVIDER: S-EPMC7611672 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature